Anti-SARS-CoV-1, Spike (Clone COV1-100)-Purified No Carrier Protein
Shipping Info:
For estimated delivery dates, please contact us at support@abeomics.com
| Amount : | 1 mg |
| Isotype : | Human IgG1Lambda |
| Purification : | Purity: >=90% monomer by analytical SEC and SDS-Page Preparation: Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
| Content : | Concentration: >=1.0 mg/ml Formulation: This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
| Storage condition : | This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at <= -70°C.?Avoid Repeated Freeze Thaw Cycles. |
Specificity: COV1-100 targets the prefusion spike protein (S2) of SARS-CoV-1 and SARS-CoV- 2.
Antigen Distribution: Anti-SARS-CoV-1 recognizes antigens on infected cells, including respiratory epithelial cells.
Background: SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans1. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel. The COV1-100 monoclonal antibody targets the spike protein of both SARS-CoV-1 and SARS- CoV-2, demonstrating cross-reactivity. However, it does not block the ACE2 receptor and does not function as a neutralizer. The epitope targeted by COV1-100 is unknown, which indicates that more research is needed to determine its binding site and potential role in viral inhibition. Despite not being a neutralizer, COV1-100 might play a role in modulating the immune response or could be useful in combination with other antibodies that have neutralizing capabilities, providing a broader spectrum of antiviral activity.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
